Ultime notizie per TPG RE Finance Trust (NYSE:TRTX) Azioni

TPG RE Finance Trust

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.

TPG RE Finance Trust Inc

S&P/TSX Composite BuyBack Total Return Index (USD)

S&P/TSX GLBM TR$

S&P/TSX GLBMNUTR

S&P/TSX High Income Energy TR Idx (USD)

TPG RE Finance Trust, Inc. 6.25% Series C Cumulative Redeemable Preferred Stock, $0.001 par value per share

<p>Piper Sandler  analyst Thomas Champion   reiterates Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Overweight and raises the price target from $62 to $73.</p>


News

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Overweight on Zillow Gr, Raises Price Target to $73

<p>On Thursday, <strong>Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), announced the <strong>final results of a new scientific study</strong>, &#8220;Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV).&#8221; Results showed that cannabis extract significantly reduces chemotherapy-induced vomiting.</p>
<p>"These findings are encouraging for cancer patients undergoing chemotherapy," stated <strong>Denise Faltischek,</strong> chief strategy officer and head of international at Tilray Brands. "This study is a crucial step in improving patient care and quality of life. Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV.&#8221;</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41694779/tilray-high-tide-glass-house-how-top-cannabis-companies-deal-with-financial-pressures">Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures</a></strong></p>
<p><em><strong>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</strong></em></p>
<h2 class="wp-block-heading"><strong>Study Highlights</strong></h2>
<p>The randomized, placebo-controlled trial tested the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.</p>
<p>The study found the cannabis extract significantly improved the rate of complete response from 8% with placebo to 24% with THC: CBD, with no use of additional medications. Benefits included reduced nausea and fewer daily vomits. </p>
<p>However, some side effects<strong> </strong>were noted, such as sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%). From 2016 to 2022, 147 participants were recruited for the study.</p>
<h2 class="wp-block-heading"><strong>Tilray Launches ‘Men's Health on Tap' Podcast</strong></h2>
<p>Meanwhile, Tilray Brands also announced the launch of &#8220;Men&#8217;s Health on Tap,&#8221; a new podcast series hosted by doctors, <strong>Dr. John P. Sfakianos</strong>, MD, associate professor, Department of Urology at the Icahn School of Medicine and <strong>Dr. Steven A. Kaplan</strong>, MD, professor, Department of Urology at the Icahn School of Medicine. The podcast aims to break down stigmas, open a conversation and and invite listeners to discuss important men&#8217;s health topics.</p>
<p>Sfakianos and Kaplan noted that many men hesitate to discuss health concerns and may delay visiting the doctor, which can lead to more serious, undiagnosed conditions. In episode one of the podcast, they encourage men to discuss these topics openly and emphasize that regular check-ups and early intervention can help them lead healthier, longer lives.</p>
<p>&#8220;We are excited to launch &#8216;Men&#8217;s Health on Tap&#8217; and break down stigmas around men&#8217;s health,&#8221; stated Sfakianos. &#8220;Our goal is to provide valuable information and resources that will help men take control of their health and wellness.&#8221;</p>
<p><strong>Price Action</strong></p>
<p><strong>Tilray shares traded 1.30% higher at $1.56 per share during Thursday's pre-market session</strong></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40919186/cannabis-giant-tilray-expands-medical-marijuana-portfolio-with-redecan-launch-in-australia">Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia</a></li>
</ul>
<p><em>Photo: Courtesy of Tinnakorn jorruang via Shutterstock</em></p>


Cannabis

TLRY

Cannabis Extract Significantly Reduces Chemotherapy-Induced Vomiting, Tilray-Backed Study Reveals

<p>Barclays  analyst Ryan Macwilliams   maintains AudioCodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) with a Underweight and lowers the price target from $10 to $9.</p>


AUDC

Barclays Maintains Underweight on AudioCodes, Lowers Price Target to $9

<p>Barclays  analyst Blayne Curtis   maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight and raises the price target from $125 to $145.</p>


Barclays Maintains Overweight on ARM Holdings, Raises Price Target to $145

<p>Piper Sandler  analyst Peter Keith   maintains Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Neutral and raises the price target from $3.5 to $3.75.</p>


COOK

Piper Sandler Maintains Neutral on Traeger, Raises Price Target to $3.75

<p>Benchmark  analyst Mark Miller   maintains Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) with a Buy and lowers the price target from $42 to $38.</p>


VECO

Benchmark Maintains Buy on Veeco Instruments, Lowers Price Target to $38

<p><strong>BlackBerry Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) shares are trading<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> relatively flat in the morning session on Thursday.</a></p>
<p>Yesterday, the company announced that Hyundai Mobis, a subsidiary of the <strong>Hyundai Motor Grou</strong>p (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>), has selected BlackBerry QNX<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac41793335/hyundai-mobis-selects-blackberry-qnx-to-power-next-generation-digital-cockpit-platform" rel="noreferrer noopener"> to power its next-generation digital cockpit platform.</a></p>
<p>Hyundai Mobis will use BlackBerry&#8217;s QNX Hypervisor for Safety&nbsp;and&nbsp;QNX Advanced Virtualization Frameworks&nbsp;(QAVF) for its next-generation digital cockpit platform.</p>
<p>&#8220;With BlackBerry QNX technology underpinning our next generation digital cockpit platform, together we are helping to deliver a smarter and more technologically sophisticated future for drivers and passengers alike, without sacrificing safety, security or reliability,&#8221; said Sung-Hoon Lee, SVP of Sales Division at Hyundai Mobis.</p>
<p>QNX&#8217;s foundational software supports digital cockpits and advanced driver assistance systems (ADAS) to infotainment systems and domain controllers at lower cost.</p>
<p><strong>Also Read:<a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/11/41794596/bitcoin-ethereum-dogecoin-slingshot-to-the-moon-after-trump-victory-but-sharp-correction-m" rel="noreferrer noopener"> Bitcoin, Ethereum, Dogecoin Slingshot To The Moon After Trump Victory But &#8216;Sharp&#8217; Correction Might Be In Store: Analyst Views BTC Between $80-90K By End Of Year</a></strong></p>
<p>&#8220;We&#8217;re confident that automakers worldwide will embrace Hyundai Mobis&#8217; cutting-edge digital cockpit platform as they enhance the safety and personalization of the in-car experience,&#8221; said Dhiraj Handa, VP, Asia Pacific region at BlackBerry QNX.</p>
<p>On October 31, BlackBerry announced an expansion of its long-standing collaboration by inking a pact of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/ac41650377/blackberry-qnx-introduces-software-defined-functional-safety-platform-in-collaboration-with-intel" rel="noreferrer noopener">BlackBerry QNX with Intel Corporation</a>.&nbsp;</p>
<p>Last month, the company announced details of profitability for its IoT and Cybersecurity divisions, including&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41364627/why-blackberry-shares-are-gaining-today" rel="noreferrer noopener">strategic options for the Cylance business.</a></p>
<p>BlackBerry projected FY25 cyber revenues between $350 million and $365 million and optimistic about achieving break-even results, signaling a potential turnaround after previous challenges.</p>
<p>In a press release dated<a target="_blank" href="https://www.blackberry.com/us/en/pdfviewer?file=/content/dam/bbcomv4/blackberry-com/en/company/investors/financial-reports/2025/q22025/Q2-FY25-Earnings-Press-Release.pdf" rel="noreferrer noopener"> September 26</a>, the company said it expects FY25 revenues of $591 million – $616 million.</p>
<p>According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, BB stock has lost 39% in the past year.</p>
<p><strong>Price Action: </strong>BB shares are trading higher by 0.31% to $2.297 at last check Thursday.</p>
<p><strong>Read Next:&nbsp;&nbsp;&nbsp;&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41778985/the-bitcoin-act-of-2024-is-a-significant-proposal-will-it-redefine-us-crypto-regulation" target="_blank" rel="noreferrer noopener">The BITCOIN Act Of 2024 ‘Is A Significant Proposal' — Will It Redefine US Crypto Regulation?</a></strong></li>
</ul>


Equities

Markets

General

HYMTF

BlackBerry Powers Up: Hyundai Mobis Chooses QNX For Next-Gen Digital Cockpit

<p><strong>Welltower</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) just disclosed its Q3 earnings on Monday, October 28, 2024 at 04:05 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Welltower beat estimated earnings by 7.000000000000001%, reporting an EPS of $1.11 versus an estimate of $1.04.</p>
<p>Revenue was up $394.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.04 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Welltower's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.04</td>
<td>1.01</td>
<td>0.94</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.11</td>
<td>1.05</td>
<td>1.01</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.95B</td>
<td>1.89B</td>
<td>1.81B</td>
<td>1.75B</td>
<td>1.63B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.06B</td>
<td>1.82B</td>
<td>1.56B</td>
<td>1.75B</td>
<td>1.66B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Welltower management provided guidance for FY 2024, expecting earnings between $4.27 and $4.33 per share.</p>
<h3>Peer Performance in Recent Earnings</h3>
<p>With Welltower's earnings data now available, it's crucial to gauge how its competitors, including Healthpeak Properties, Sabra Health Care REIT, and National Health Investors, have been performing.</p>
<ul>
<li>Healthpeak Properties, earnings revealed on October 24, 2024, exhibited robust performance this quarter. Contrary to the market's projected EPS of $0.44, Healthpeak Properties exceeded expectations with an EPS of $0.45, reflecting an increase of 2.27% compared to estimates. This outcome is likely to gain investor confidence</li>
<li>Sabra Health Care REIT announced strong earnings on October 31, 2024, surpassing market expectations. Despite an estimated EPS of $0.35, Sabra Health Care REIT's actual EPS was $0.35, reflecting a 0.0% increase.</li>
<li>The latest earnings report from National Health Investors on November 05, 2024 showed a downturn in performance, with results falling short of expectations. Despite the market's EPS estimate of $1.08, National Health Investors reported an EPS of $1.03, marking a -4.63% decrease.</li>
</ul>
<h3>Analysis of Competitors' Quarterly Earnings and Stock Performance</h3>
<p>The analysis presented here offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welltower</td>
<td>October 28, 2024</td>
<td style="text-align: right;">1.04</td>
<td style="text-align: right;">1.11</td>
<td>6.73%</td>
<td>$130.57</td>
<td>$133.62</td>
<td>2.34%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>October 24, 2024</td>
<td style="text-align: right;">0.44</td>
<td style="text-align: right;">0.45</td>
<td>2.27%</td>
<td>$23.0</td>
<td>$22.66</td>
<td>-1.48%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>October 31, 2024</td>
<td style="text-align: right;">0.35</td>
<td style="text-align: right;">0.35</td>
<td>0.0%</td>
<td>$19.4</td>
<td>$19.78</td>
<td>1.96%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>November 05, 2024</td>
<td style="text-align: right;">1.08</td>
<td style="text-align: right;">1.03</td>
<td>-4.63%</td>
<td>$76.73</td>
<td>$76.75</td>
<td>0.03%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
<p>The comparison table below presents estimated and announced revenue figures for Welltower's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welltower</td>
<td>1.95B</td>
<td>2.06B</td>
<td>5.44%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>688.98M</td>
<td>700.40M</td>
<td>1.66%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>172.34M</td>
<td>178.00M</td>
<td>3.28%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>79.21M</td>
<td>82.94M</td>
<td>4.72%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Welltower <a href="https://www.benzinga.com/quote/WELL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

WELL

Welltower Earnings Report: Q3 Overview

Trading Ideas

DXYZ

Destiny Tech100 Inc. Shares Resume Trade

<p>Piper Sandler  analyst Matt Farrell   reiterates Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Overweight and raises the price target from $13 to $18.</p>


UPWK

Piper Sandler Reiterates Overweight on Upwork, Raises Price Target to $18

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and maintains $54 price target.</p>


Telsey Advisory Group Maintains Outperform on Tapestry, Maintains $54 Price Target

<p>Benchmark  analyst Mike Hickey   reiterates AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) with a Hold.</p>


Benchmark Reiterates Hold on AMC Enter Hldgs

Destiny Tech100 Inc. Shares Halted To The Upside; Stock Now Up 42.35%

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) with a Market Perform and maintains $3 price target.</p>


OLPX

Telsey Advisory Group Maintains Market Perform on Olaplex Hldgs, Maintains $3 Price Target

<p>Piper Sandler  analyst Matt Farrell   reiterates Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) with a Neutral and raises the price target from $7 to $8.</p>


BMBL

Piper Sandler Reiterates Neutral on Bumble, Raises Price Target to $8

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $50 price target.</p>


SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $50 Price Target

<p><strong>Hyatt Hotels</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) announced its Q3 earnings on Thursday, October 31, 2024 at 06:55 AM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Hyatt Hotels missed estimated earnings by -32.0%, reporting an EPS of $0.94 versus an estimate of $1.38.</p>
<p>Revenue was up $7.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.36, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at Hyatt Hotels's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.38</td>
<td>1.17</td>
<td>0.92</td>
<td>0.39</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.94</td>
<td>1.53</td>
<td>0.71</td>
<td>0.64</td>
<td>0.70</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.57B</td>
<td>1.74B</td>
<td>1.71B</td>
<td>1.60B</td>
<td>1.64B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.63B</td>
<td>1.70B</td>
<td>1.71B</td>
<td>1.66B</td>
<td>1.62B</td>
</tr>
</tbody>
</table>
</p>
<h3>Peer Performance in Recent Earnings</h3>
<p>With Hyatt Hotels's earnings data in hand, it's essential to compare its metrics to those of similar companies, including Norwegian Cruise Line, Viking Holdings, and Global Business Travel.</p>
<ul>
<li>Norwegian Cruise Line, earnings revealed on October 31, 2024, exhibited robust performance this quarter. Contrary to the market's projected EPS of $0.94, Norwegian Cruise Line exceeded expectations with an EPS of $0.99, reflecting an increase of 5.32% compared to estimates. This outcome is likely to gain investor confidence</li>
<li>Viking Holdings reported earnings on August 22, 2024 that fell short of expectations, with an actual EPS of $0.37 compared to the market's estimate of $0.65, resulting in a -43.08% decrease.</li>
<li>On November 05, 2024, Global Business Travel unveiled earnings that were below market expectations, with an actual EPS of $-0.28 compared to an estimated EPS of $-0.03, resulting in a -833.33% decrease.</li>
</ul>
<h3>Unpacking Competitors' Quarterly Earnings and Stock Performance</h3>
<p>This analytical review offers valuable insights into how the market has perceived the most recent earnings updates from major competitors. It outlines the forecasted and disclosed earnings per share (EPS) for each company, as well as the related stock prices at the end of the announcement day and the start of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyatt Hotels</td>
<td>October 31, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">0.94</td>
<td>-31.88%</td>
<td>$145.45</td>
<td>$145.42</td>
<td>-0.02%</td>
</tr>
<tr>
<td>Norwegian Cruise Line</td>
<td>October 31, 2024</td>
<td style="text-align: right;">0.94</td>
<td style="text-align: right;">0.99</td>
<td>5.32%</td>
<td>$25.34</td>
<td>$25.25</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Viking Holdings</td>
<td>August 22, 2024</td>
<td style="text-align: right;">0.65</td>
<td style="text-align: right;">0.37</td>
<td>-43.08%</td>
<td>$33.22</td>
<td>$33.83</td>
<td>1.84%</td>
</tr>
<tr>
<td>Global Business Travel</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.28</td>
<td>-833.33%</td>
<td>$7.73</td>
<td>$7.87</td>
<td>1.81%</td>
</tr>
</tbody>
</table>
</p>
<h3>Peer Revenue Comparison: Estimated vs. Announced Revenue</h3>
<p>Here's a comparison table presenting estimated and announced revenue figures for Hyatt Hotels's peers. This comparison offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyatt Hotels</td>
<td>1.57B</td>
<td>1.63B</td>
<td>3.76%</td>
</tr>
<tr>
<td>Norwegian Cruise Line</td>
<td>2.77B</td>
<td>2.81B</td>
<td>1.34%</td>
</tr>
<tr>
<td>Viking Holdings</td>
<td>1.43B</td>
<td>1.59B</td>
<td>10.98%</td>
</tr>
<tr>
<td>Global Business Travel</td>
<td>613.53M</td>
<td>597M</td>
<td>-2.69%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Hyatt Hotels <a href="https://www.benzinga.com/quote/H/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hyatt Hotels Earnings Review: Q3 Summary

TTEC

TTEC Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Down -15.5%

Offerings

IPOs

ADUR

Aduro Clean Technologies Prices $4M Offering  Of 941,177 Shares At $4.25/Share

<p>Benchmark  analyst Mark Zgutowicz   maintains LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) with a Buy and lowers the price target from $48 to $42.</p>


RAMP

Benchmark Maintains Buy on LiveRamp Holdings, Lowers Price Target to $42

There's a lot to be optimistic about in the Real Estate sector as 2 analysts just weighed in on Cellnex Telecom SA (CLNXF – Research Report) and Tp...

Analysts Are Bullish on Top Real Estate Stocks: Cellnex Telecom SA (CLNXF), Tpg Re Finance (TRTX)

TPG RE Finance Trust: The Preferreds Are A Buy As Rate Cuts Loom

In a report released today, Steven Delaney from JMP Securities maintained a Buy rating on Tpg Re Finance (TRTX – Research Report), with a price tar...

Tpg Re Finance (TRTX) Receives a Buy from JMP Securities

TPG RE Finance Trust 6.25% Series C Preferred Stock declares $0.3906 dividend

TPG RE Finance Trust declares $0.24 dividend

Here are the major earnings after the close today

TPG RE Finance Trust Non-GAAP EPS of $0.28 beats by $0.01

JMP Securities Sticks to Its Buy Rating for Tpg Re Finance (TRTX)

Tpg Re Finance (TRTX – Research Report), the Real Estate sector company, was revisited by a Wall Street analyst yesterday. Analyst Donald Fandetti ...

TPG RE Finance Trust: Stability, Value Potential, and Attractive Dividend Yield Justify Buy Rating

Pivotal Decisions

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

ALSN

APAM

ATGE

ATOM

BGFV

BLDG

BMRN

BRSP

BXMT

CAKE

CHCT

CLNXF

CTRE

CUBE

CURB

ENVX

EQIX

EXEL

EXLS

FREL

FSLR

GOOG

GQRE

HAUS

HAUZ

HOMZ

HRZN

IFGL

ILPT

INDS

INVH

IRET

JBGS

KBWY

LBTYA

LBTYK

LFUS

LFVN

LSTR

LYSCF

MDLZ

MFIN

MORT

NAIL

NETL

NREF

NURE

NXRT

NYMT

NYMTI

NYMTL

NYMTM

NYMTN

NYMTZ

PECO

PFFR

PILBF

PLDGP

PPTY

PRTS

QRVO

RDDT

RDOG

REET

REGCO

REGCP

REIT

RIET

RITM

RMBS

ROOF

SAGE

SBAC

SBRA

SCHH

SEVN

SITC

SNAP

SRVR

STAG

STWD

TRTX

USRT

VIOO

VRAI

VRNS

WERN

XLRE

Press Releases

TPG RE Finance Trust, Inc. Reports Operating Results for the Quarter Ended March 31, 2024

TPG RE Finance Trust, Inc. to Participate in Nareit's REITweek: 2024 Investor Conference

TPG RE Finance Trust, Inc. Declares Cash Dividend on Series C Cumulative Redeemable Preferred Stock

TPG RE Finance Trust, Inc. Declares Cash Dividend on Common Stock

TPG RE Finance Trust, Inc. Announces Second Quarter 2024 Earnings Release and Conference Call Dates

TPG RE Finance Trust, Inc. Reports Operating Results for the Quarter Ended June 30, 2024

TPG RE Finance Trust, Inc. Announces Third Quarter 2024 Earnings Release and Conference Call Dates

TPG RE Finance Trust, Inc. Reports Operating Results for the Quarter Ended September 30, 2024

Comments

TPG RE Finance Trust

Notizie

Ultime notizie per TPG RE Finance Trust (NYSE:TRTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO